Synthetic Lethal Therapy for KRAS Mutant Non-small-cell Lung Carcinoma with Nanoparticle-mediated CDK4 siRNA Delivery

The KRAS mutation is present in ~20% of lung cancers and has not yet been effectively targeted for therapy. This mutation is associated with a poor prognosis in non-small-cell lung carcinomas (NSCLCs) and confers resistance to standard anticancer treatment drugs, including epidermal growth factor re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mao, Cheng-Qiong, Xiong, Meng-Hua, Liu, Yang, Shen, Song, Du, Xiao-Jiao, Yang, Xian-Zhu, Dou, Shuang, Zhang, Pei-Zhuo, Wang, Jun
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015238/
https://ncbi.nlm.nih.gov/pubmed/24496383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2014.18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados